Stay updated with breaking news from Abiomed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries.
AbbVie trades at a higher valuation of 5.5x trailing revenues, compared to 4.6x for JNJ.
Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries.
Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open c
Johnson & Johnson (JNJ) has announced that it is buying Shockwave Medical (SWAV) for $12.5 billion U.S. In a news release, Johnson & Johnson said that the deal will increase its portfolio of medical devices used to treat heart disease and other ...